Is Furmonertinib a targeted therapy drug?

Yes, Furmonertinib is a targeted therapy drug, classified as a third-generation EGFR-TKI. It can specifically inhibit EGFR gene mutations (such as T790M, Del19, L858R, etc.) and exerts its therapeutic effect by blocking the signaling pathway responsible for tumor cell proliferation.